Oncternal Therapeutics (ONCT) PT Raised to $30 at H.C. Wainwright
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/13/2026
- Nasdaq falls ahead of earnings, economic data while oil rallies
- Oil prices rise on Saudi Arabia attacks, overshadowing Trump's diesel deal
- Will surging equity supply derail the U.S. bull market? Goldman Sachs weighs in
- Broadcom CEO says many AI investors are gamblers
- "Not buying Chipotle": Starbucks squashes blockbuster acquisition speculation
Tweet
Share
E-mailGet Alerts ONCT Hot Sheet
Price: $0.53 --0%
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Rating Summary:
3 Buy, 4 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 19 | Down: 21 | New: 69
Join SI Premium – FREE
H.C. Wainwright analyst Raghuram Selvaraju raised the price target on Oncternal Therapeutics (NASDAQ: ONCT) to $30.00 (from $2.00) while maintaining a Buy rating.
You May Also Be Interested In
- Terna SpA (TRN:IM) (TERRF) PT Raised to EUR8.90 at Goldman Sachs
- Raymond James (RJF) PT Lowered to $166 at Truist Securities
- LPL Financial Holdings (LPLA) PT Lowered to $356 at Truist Securities
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
